| Description |
Sitafloxacin (DU6859a) monohydrate is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin monohydrate shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin monohydrate can be used for the research of respiratory tract infection and urinary tract infection[1][2].
|
| Related Catalog |
|
| In Vitro |
Sitafloxacin (DU6859a) monohydrate shows antibacterial activities with MIC of 0.03, 0.12, 0.06 mg/L for wild-type ATCC 49619, gyrA mutant SP39, parC mutant 1026523 streptococcus pneumoniae stran, respectively[1]. Sitafloxacin (DU6859a) monohydrate shows antibacterial activities for quinolone-susceptible strains of streptococcus pneumoniae with MIC of 0.03, 0.03 mg/L for EG 00093 and EG 00218 strain, respectively[1]. Sitafloxacin (DU6859a) monohydrate shows inhibition for DNA gyrase and topoisomerase IV (TopoIV) with >IC50s of 4.38, 3.12 mg/L, respectively[1].
|
| In Vivo |
Sitafloxacin (DU6859a; 12.5-100 mg/kg; i.g.; daily for 4 weeks; BALB/c female mice) monohydrate has antibacterial activity. M. ulcerans cells could be isolated from the inoculated footpads and there was no evidence of footpad swelling[2]. Animal Model: BALB/c female mice[2] Dosage: 12.5, 25, 50 and 100 mg/kg Administration: Oral gavage; daily, for 4 weeks Result: Inhibits the growth of Mycobacterium ulcerans and the M. ulcerans cells.
|
| References |
[1]. Okumura R, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104. [2]. Dhople AM, et al. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice. J Chemother. 2003 Feb;15(1):47-52.
|
